安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ribociclib: Uses, Dosage, Side Effects, Warnings - Drugs. com
Ribociclib is a targeted treatment used to treat breast cancer that is hormone receptor-positive, HER2-negative breast and has spread (metastasized) or cannot be removed by surgery Ribociclib is given in combination with other cancer medicines such as letrozole (Femara) or fulvestrant (Faslodex)
- Ribociclib - Wikipedia
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer [4] Ribociclib is a kinase inhibitor [4] It was developed by Novartis and Astex Pharmaceuticals [6]
- HIGHLIGHTS OF PRESCRIBING INFORMATION • Increased QT . . . - Novartis
Pre perimenopausal women, or men, treated with the combination KISQALI plus an aromatase inhibitor or fulvestrant, should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards
- Ribociclib (Kisqali) - Uses, How to Take and Side Effects
Ribociclib is a targeted or biological therapy drug When used to treat breast cancer, ribociclib is taken alongside hormone (endocrine) therapy Ribociclib is the drug’s non-branded name Its brand name is Kisqali It belongs to a group of drugs called CDK (cyclin dependent kinase) inhibitors
- Ribociclib (oral route) - Mayo Clinic
Ribociclib is used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer It is used in combination with an aromatase inhibitor to treat stage II and III early breast cancer with a high risk of coming back
- Ribociclib Succinate - NCI - National Cancer Institute
Ribociclib succinate works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow Blocking these proteins may slow or stop the growth of cancer cells Ribociclib succinate is a type of targeted therapy drug called a kinase inhibitor
- Kisqali (ribociclib) dosing, indications, interactions, adverse effects . . .
Treat pre perimenopausal women or men who receive ribociclib plus an aromatase inhibitor or fulvestrant with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical
- Ribociclib (Kisqali®) - Macmillan Cancer Support
Ribociclib is used to treat breast cancer that is oestrogen-receptor positive (ER positive) and HER2 negative It may be used if the cancer has spread: from the breast to other parts of the body (metastatic or secondary breast cancer)
|
|
|